BioPharma Resources

Drug Trial Radar · NCT00514007

Study of Continuous OSI-906 Dosing

A Phase I Dose Escalation Study of Continuous Oral OSI-906 Dosing in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

95

Actual

Start

Jun 18, 2007

Primary completion

Mar 19, 2012

Study completion Mar 19, 2012

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Aug 9, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) on both Once Daily (QD) and Twice Daily (BID) schedules.

Conditions

  • Advanced Solid Tumors

Interventions

  • OSI-906Drug

    OSI-906 administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the maximum tolerated dose (MTD) for both the once daily (QD) and twice daily (BID) dosing schedules and establish a recommended phase 2 dose of oral OSI-906Time frame: 21 days

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Vanderbilt Universtiy Medical Center

    Nashville, Tennessee

  • The Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.